Correlation of NRAS mutations with clinical response to high-dose IL-2 in patients with advanced melanoma (Q35621653)

9 August 2017

title

Correlation of NRAS mutations with clinical response to high-dose IL-2 in patients with advanced melanoma (English)

1 reference

9 August 2017

Patrick Hwu

1 reference

9 August 2017

Richard W Joseph

1 reference

9 August 2017

Ryan J Sullivan

1 reference

9 August 2017

Robyn Harrell

1 reference

9 August 2017

Katherine Stemke-Hale

1 reference

9 August 2017

David Panka

1 reference

9 August 2017

George Manoukian

1 reference

9 August 2017

Andrew Percy

1 reference

9 August 2017

Roland L Bassett

1 reference

9 August 2017

Chaan S Ng

1 reference

9 August 2017

Laszlo Radvanyi

1 reference

9 August 2017

Michael B Atkins

1 reference

9 August 2017

Michael A Davies

1 reference

9 August 2017

publication date

1 January 2012

1 reference

9 August 2017

published in

Journal of Immunotherapy

1 reference

9 August 2017

1 reference

9 August 2017

1 reference

9 August 2017

page(s)

66-72

1 reference

9 August 2017

cites work

Global cancer statistics

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3241890

Inhibition of Mutated, Activated BRAF in Metastatic Melanoma

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3241890

Analysis of the genome to personalize therapy for melanoma

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3241890

Selective BRAFV600E inhibition enhances T-cell recognition of melanoma without affecting lymphocyte function

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3241890

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3241890

Final version of 2009 AJCC melanoma staging and classification

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3241890

Serum vascular endothelial growth factor and fibronectin predict clinical response to high-dose interleukin-2 therapy

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3241890

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3241890

Serum lactate dehydrogenase levels and glycolysis significantly correlate with tumor VEGFA and VEGFR expression in metastatic CRC patients

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3241890

Role of the mitogen-activated protein kinase signaling pathway in the regulation of human melanocytic antigen expression

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3241890

The BRAF-MAPK signaling pathway is essential for cancer-immune evasion in human melanoma cells

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3241890

Management of cutaneous melanoma

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3241890

Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3241890

Managing toxicities of high-dose interleukin-2.

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3241890

Guidelines for the safe administration of high-dose interleukin-2.

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3241890

Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3241890

Improved survival with vemurafenib in melanoma with BRAF V600E mutation

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3241890

gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma

25 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3241890

Clinical outcome and pathological features associated with NRAS mutation in cutaneous melanoma.

25 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3241890

Prognostic factors that determine the long-term survival of patients with unresectable metastatic melanoma

25 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3241890

The MAPK pathway in melanoma

25 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3241890

Ultraviolet radiation and melanoma: a systematic review and analysis of reported sequence variants

25 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3241890

Carbonic anhydrase IX expression predicts outcome of interleukin 2 therapy for renal cancer.

25 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3241890

Factors associated with response to high-dose interleukin-2 in patients with metastatic melanoma

25 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3241890

High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993

25 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3241890

Abnormally enhanced blood concentrations of vascular endothelial growth factor (VEGF) in metastatic cancer patients and their relation to circulating dendritic cells, IL-12 and endothelin-1

25 September 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/22130161

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/22130161

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

2010 TNM staging system for cutaneous melanoma...and beyond

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/22130161

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1097/CJI.0B013E3182372636

1 reference

9 August 2017

1 reference

9 August 2017

1 reference